Sugi Predict

Sugi Predict / Compounds / SCHEMBL759137

SCHEMBL759137

SCHEMBL759137

COC(=O)CCC(C)(C)C(=O)OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.52
▸ KMT2A Q03164 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ LMNA P02545 3/20 0.39
▸ CA12 O43570 2/20 0.39
▸ CA14 Q9ULX7 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ HSD17B10 Q99714 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ MGAM O43451 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ SI P14410 1/20 0.37
▸ MGAM2 Q2M2H8 1/20 0.37
▸ DGAT1 O75907 1/20 0.37
▸ CNR1 P21554 1/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ TET2 Q6N021 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27834061 0.98 TSHR (0.50) TSHRKMT2AMEN1LMNACA12
SCHEMBL8433296 0.87 TSHR (0.56) TSHRKMT2AMEN1LMNACA12
SCHEMBL28887136 0.85 TSHR (0.54) TSHRKMT2AMEN1LMNACA12
SCHEMBL14891456 0.84 TSHR (0.52) TSHRKMT2ALMNARECQLALDH1A1
SCHEMBL14809987 0.84 TSHR (0.52) TSHRKMT2ALMNARECQLALDH1A1
SCHEMBL28738660 0.84 TSHR (0.52) TSHRKMT2ALMNARECQLALDH1A1
SCHEMBL2022397 0.83 DGAT1 (0.44) TSHRRECQLHSD17B10ALDH1A1MGAM
SCHEMBL3177122 0.82 TSHR (0.52) TSHRKMT2AMEN1LMNACA12
SCHEMBL28179946 0.82 TSHR (0.52) TSHRKMT2AMEN1LMNACA12
SCHEMBL3283628 0.82 DGAT1 (0.37) TSHRLMNAKDM4ERECQLDGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115210310-A Composition and method for waste polypropylene degradation 诺弗洛普有限公司 2022-10-18 — — CN claimed
CN-107728426-A Photoresist composition and method for forming metal pattern using the same 三星显示有限公司 2018-02-23 — — CN claimed
US-11866432-B2 Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors INCYTE CORPORATION (US) 2024-01-09 — — US disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 — — US disclosed
CN-115210310-A Composition and method for waste polypropylene degradation 诺弗洛普有限公司 2022-10-18 — — CN disclosed
CN-114040764-A Cyclin-dependent kinase 2 biomarkers and uses thereof 因赛特公司 2022-02-11 — — CN disclosed
US-20220009923-A1 DIHYDROPYRIDO[2,3-D]PYRIMIDINONE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION 2022-01-13 — — US disclosed
US-20220009923-A1 DIHYDROPYRIDO[2,3-D]PYRIMIDINONE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION 2022-01-13 — — US disclosed
EP-3923949-A1 CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND USES THEREOF Incyte Corporation (US) 2021-12-22 — — EP disclosed
US-11066404-B2 Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors INCYTE CORPORATION (US) 2021-07-20 — — US disclosed
US-11066404-B2 Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors INCYTE CORPORATION (US) 2021-07-20 — — US disclosed
WO-2008020902-A1 SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2008-02-21 — — WO disclosed
WO-2008020902-A1 SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2008-02-21 — — WO disclosed
WO-2007133491-A1 SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-11-22 — — WO disclosed
US-20070265225-A1 Substituted monocyclic CGRP receptor antagonists MERCK SHARP & DOHME LLC 2007-11-15 — — US disclosed
US-20070265225-A1 Substituted monocyclic CGRP receptor antagonists MERCK SHARP & DOHME LLC 2007-11-15 — — US disclosed
US-20070265225-A1 Substituted monocyclic CGRP receptor antagonists MERCK SHARP & DOHME LLC 2007-11-15 — — US disclosed
WO-2007008037-A1 NOVEL CHROMEN-2-ONE BASED HYDROXAMIC ACID DERIVATIVES HAVING ANTI-INFLAMMATORY ACTIVITY, THE PREPARATION THEREOF AND A COMPOSITION CONTAINING THE SAME FOR TREATING INFLAMMATORY DISEASE JEIL PHARMACEUTICAL CO., LTD. (KR) 2007-01-18 — — WO disclosed
US-6586613-B1 Compounds such as 5-(tert-butyldimethylsiloxy)-7,7-dimethyl -4(4-fluorophenyl)-3-(hydroxy-(4-trifluorophenyl)-methyl)-2-isopropyl -5,6,7,8-tetrahydronaphthalene, used as antagonists for cholesteryl ester transferase protein; hyperlipemia BAYER AKTIENGELLSCHAFT (DE) 2003-07-01 — — US disclosed
US-6326372-B1 BENIGN PROSTATE HYPERPLASIA MERCK & CO., INC. 2001-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11866432-B2 Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors CDK2, CDK4, CDK3 TSHR 4125/4885KMT2A 729/4885MEN1 2878/4885
US-11066404-B2 Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors CDK2, CDK4, CDK3 TSHR 4125/4885KMT2A 729/4885MEN1 2878/4885
US-20220009923-A1 DIHYDROPYRIDO[2,3-D]PYRIMIDINONE COMPOUNDS AS CDK2 INHIBITORS CDK2, CDK4, CDK3 TSHR 4125/4885KMT2A 729/4885MEN1 2878/4885
US-20070265225-A1 Substituted monocyclic CGRP receptor antagonists QRFPR, CALCRL, EDNRB TSHR 555/4885KMT2A 2761/4885MEN1 567/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV TSHR 4669/4885KMT2A 3383/4885MEN1 4306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.